Filing and period
The supplied filing is IsoRay, Inc.’s Form 10-Q, not a Perspective Therapeutics, Inc. filing. It reports the three months ended September 30, 2013, the first quarter of IsoRay’s fiscal 2014; the metadata’s company and “2013 Q1” labels do not match the filing. Figures below are for IsoRay and its subsidiaries.
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2013 | Comparable 2012 quarter |
|---|---|---|
| Product sales | $1.050 million | $1.056 million |
| Gross loss / margin | $77,308 / (7%) | $20,425 / (2%) |
| Operating expenses | $1.157 million | $1.102 million |
| Operating loss | $1.235 million | $1.123 million |
| Net loss | $1.271 million | $994,000 |
| Net loss applicable to common shareholders | $2.000 million | $996,000 |
| Basic and diluted loss per share | $0.06 | $0.03 |
| Cash used in operations | $892,000 | $939,000 |
| Cash and cash equivalents at period end | $5.284 million | $5.029 million |
Revenue was nearly flat year over year: prostate sales declined 3% to $853,000, while other product sales rose 13% to $197,000. Cost of product sales rose 5%, producing a larger gross loss. Management attributed increased production costs partly to the medical device tax and property taxes, and to higher GliaSite RTS costs. Sales and marketing expense increased 14%, while research and development and general and administrative expenses were relatively stable.
The $726,378 preferred-stock deemed dividend increased the loss applicable to common shareholders; it was not an additional operating expense. The warrant derivative liability produced a $36,000 expense in the quarter, versus $129,000 of income in the prior-year quarter.
At September 30, current assets were $6.902 million and current liabilities $970,000. Total liabilities were $1.920 million, including an $810,000 asset retirement obligation and a $140,000 warrant derivative liability; the balance sheet presents no conventional debt balance. Net financing cash flow was $3.281 million, primarily from an August 2013 public offering. Investing cash outflow was $4,631. The company reported approximately $4.91 million of cash and no short-term investments as of November 12, 2013.
Capital, outlook, and risks
The August 2013 underwritten offering generated $3.704 million gross and $3.281 million net proceeds. It included common and Series D preferred units and warrants; the preferred stock is convertible and the offering materially increased potential dilution. At September 30, potential dilutive securities totaled approximately 13.2 million, although excluded from diluted loss per share as antidilutive.
Management estimated monthly required cash operating expenditures of approximately $297,000 and expected capital expenditures below $200,000 for fiscal 2014. It believed cash on hand at November 12 would cover operations and capital requirements for at least 12 months, assuming revenue and expenses remained at current levels. Management also cautioned that revenue and payment timing affect cash needs, and that additional financing may be needed; financing might be unavailable or dilutive. No profitability or revenue-growth assurance was given.
Management plans to pursue existing and new customers, GliaSite RTS sales, and additional treatment applications, including brain, head and neck, and lung implants. Newer applications remain at an early adoption stage, with sales dependent on a small number of physicians; facility approvals and nuclear-material license modifications can delay GliaSite adoption. The prostate brachytherapy market faces competition from other treatments, and prostate sales continued to decline.
Contingencies include a disputed know-how royalty claim, for which binding arbitration may be demanded, and environmental and radioactive-material decommissioning obligations reflected in the asset retirement obligation. The company also identifies product-liability exposure, mitigated in part by insurance. Management said the previously reported material weakness in internal control was still being remediated; the Controller was promoted to CFO effective October 1, 2013. Disclosure controls were assessed as effective, and no material change in internal control during the quarter was reported.
Most important facts to verify
- Confirm the intended issuer and reporting period: the supplied document is IsoRay’s quarter ended September 30, 2013, not a Perspective Therapeutics filing.
- Assess cash runway using subsequent cash balances, actual operating cash burn, revenue collections, and any financing after November 12, 2013.
- Review the terms and conversion or exercise conditions of the Series D preferred stock and warrants, and the resulting potential dilution.
- Track product revenue by prostate, other applications, and GliaSite RTS, including adoption and regulatory approval timelines.
- Review the status and potential exposure of the royalty dispute, radioactive-material retirement obligations, and remediation of the material weakness.